Lauren Kelly
Payments from drug & device makers
Across 493 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Seagen Inc.$868
- AbbVie$741
- E.r. Squibb & Sons, L.L.C.$659
- Novartis$651
- Daiichi Sankyo Inc.$602
- plus $8K from 54 others
What the payments were for
- Food & beverage$10,94689%
- Education$1,41811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,363 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 65 | $1,258,911 |
| PomalystPomalidomide | 24 | $603,540 |
| JakafiRuxolitinib Phosphate | 34 | $562,661 |
| Lenalidomide | 32 | $456,649 |
| IbrancePalbociclib | 17 | $271,377 |
| ImbruvicaIbrutinib | 17 | $244,301 |
| VenclextaVenetoclax | 11 | $169,725 |
| EliquisApixaban | 58 | $46,636 |
| XareltoRivaroxaban | 35 | $36,007 |
| Imatinib Mesylate | 12 | $19,359 |
| Exemestane | 21 | $4,087 |
| Hydroxyurea | 93 | $2,374 |
| Anastrozole | 19 | $822 |
| Tamoxifen Citrate | 24 | $558 |
| Gabapentin | 45 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $515 | $1,258,91165 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $659 | $603,54024 claims |
| Incyte CorporationJakafi | $199 | $562,66134 claims |
| PfizerIbrance, Eliquis | $586 | $318,01375 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $304 | $244,30117 claims |
| AbbVieVenclexta | $741 | $169,72511 claims |
| Johnson & JohnsonXarelto | $515 | $36,00735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Paoli
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.